There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warning letter would follow, shipments would stall. Managements would explain remediation plans. Analysts would estimate lost revenue, how long the corrective action could take, and whether the next inspection would be clean. Today, Sun Pharma has signed a definitive agreement to acquire Organon in an all-cash transaction that values it at an enterprise value of $11.75 billion. The number matters. But the direction matters more.